Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants

Elisabetta Metafuni, Patrizia Chiusolo, Simona Sica, Luca Laurenti, Stefania Bregante, Maria Teresa Van Lint, Alida Dominietto, Emanuele Angelucci, Andrea Bacigalupo

Research output: Contribution to journalArticlepeer-review


We studied 97 patients who developed cytomegalovirus (CMV) viremia following an allogeneic hemopoietic stem cell transplant (HSCT) between 2010 and 2015, treated with foscarnet, with the aim of assessing efficacy and safety. The donor was unrelated in 30 patients (UD) and a family HLA-haploidentical donor (HAPLO) in 67 patients: the former (UD) received a prophylaxis for graft-versus-host disease (GvHD), based on antithymocyte globulin (ATG); the latter (HAPLO) received GvHD prophylaxis, based on post-transplant cyclophosphamide (PT-CY). Renal and hematological toxicity were defined according to NCI-CTCAE4 criteria. In univariate analysis, CMV response was 84% in HAPLO vs 59% in UD grafts (p = 0.01) and 90 vs 66% (p = 0.02) for patients with a CMV viral load within or over the median value. In multivariate analysis, the CMV viral load was the strongest predictor of response to foscarnet (p = 0.02), followed by donor type (p = 0.06). Renal impairment developed in 14% of the patients. Overall survival was 69%:, advanced phase at transplant (p = 0.01) and ATG-based regimens (p = 0.02), were the only two predicting factor. In conclusion, CMV response to foscarnet treatment is predicted by a lower CMV load and GvHD prophylaxis. Renal toxicity of foscarnet is not a limiting factor.

Original languageEnglish
Pages (from-to)1560-1567
Number of pages8
JournalBone Marrow Transplantation
Issue number12
Publication statusPublished - Dec 2018


Dive into the research topics of 'Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants'. Together they form a unique fingerprint.

Cite this